| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/16/2004 | WO2003045318A3 Manipulation of cytokine levels using cd83 gene products |
| 09/16/2004 | WO2003045228A9 Methods for treating autoimmune disorders, and reagents related thereto |
| 09/16/2004 | WO2003043583A3 Treatment of immunological disorders using anti-cd30 antibodies |
| 09/16/2004 | WO2002100827A3 Method for increasing the survival of dopamine secreting cells |
| 09/16/2004 | WO2002050097A3 Anti-allergic complex molecules |
| 09/16/2004 | US20040181076 Reaction of carbazolone, forrmaldehyde and amine compound in nonaqueous solution and bonding to water, solvent |
| 09/16/2004 | US20040181069 modulators of the monoamine receptors, in particular the serotonin, dopamine and norepinephrine receptors, and the biogenic amine transporters for serotonin, dopamine and norepinephrine; |
| 09/16/2004 | US20040181062 Benzimidazole cyclooxygenase-2 inhibitor |
| 09/16/2004 | US20040181059 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 09/16/2004 | US20040181047 33 human secreted proteins |
| 09/16/2004 | US20040181035 Modified colony stimulating factor for treatment of hematopoietic disorder |
| 09/16/2004 | US20040180967 A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction |
| 09/16/2004 | US20040180959 --title-- |
| 09/16/2004 | US20040180953 B form is the most thermodynamically stable form at room temperature; a purer and more homogeneous product is produced and recrystallization is advantageously carried out by initiating with a small amount of the product |
| 09/16/2004 | US20040180952 Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same |
| 09/16/2004 | US20040180936 having an inhibitory activity on calpains and/or a trapping activity on reactive oxygen species; inflammatory and immunological diseases; disorders of the central or peripheral nervous system |
| 09/16/2004 | US20040180921 Nitrogen compounds such as 2-benzofuran-2-yl-imidazo(1,2-a) pyridine administered as g protein coupled receptor antagonists for prophylaxis of psychological and neurodegenerative disorders, and as analgesics |
| 09/16/2004 | US20040180912 for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable |
| 09/16/2004 | US20040180908 (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol |
| 09/16/2004 | US20040180904 Novel use of 2h-benzimidazol-2-one, 1,3-Dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable addition salts |
| 09/16/2004 | US20040180901 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 09/16/2004 | US20040180899 tyrosine kinase inhibitors |
| 09/16/2004 | US20040180890 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same |
| 09/16/2004 | US20040180887 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 09/16/2004 | US20040180883 Central nervous system disorders; such as 7-{2-[4-(6-Fluorobenzothiophen-3-yl)-2-methylpiperazin-1-yl]ethyl}-4,5-dihydro-7H-thieno[2,3-c]pyran-2-carboxamide |
| 09/16/2004 | US20040180881 Oxazolyl-pyrazole derivatives as kinase inhibitors |
| 09/16/2004 | US20040180880 Piperazine and piperidine derivatives |
| 09/16/2004 | US20040180878 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 09/16/2004 | US20040180877 Nicotinic acetylcholine receptor cholinergic ligands, monoamine receptor and transporter modulators; such as 1-(2-Benzo[b]thiophenyl-1,1-dioxide)-imidazolidine |
| 09/16/2004 | US20040180876 Selective beta 2-adrenoreceptor agonists; rapid onset of action, long duration; such as 3-(4-{[6-{(-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzenesulfonamide; synthesis |
| 09/16/2004 | US20040180875 Obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, sexual disorders |
| 09/16/2004 | US20040180874 5-HT6 modulators; such as 2-benzenesulfonyl-5-piperazin-1-yl-1,2,3,4-tetrahydroisoquinoline; |
| 09/16/2004 | US20040180834 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| 09/16/2004 | US20040180817 Use of tumor necrosis factor alpha p75 receptor antagonist or endothelin receptor antagonist, converting enzyme inhibitor or neutralizing agent; reducting cerebral perfusion; method of identifying candidates |
| 09/16/2004 | US20040180816 Combination comprising a p-gp inhibitor and an anti-epileptic drug |
| 09/16/2004 | US20040180434 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 09/16/2004 | US20040180338 Mutated eukariotic transalation initiation factor 2 alpha kinase3, eif2ak3, in patients with neonatal insuluin-dependant diabetes and multiple epiphyseal dyslapsia (wolcott-rallison syndrome) |
| 09/16/2004 | US20040180105 Use of a Ginkgo biloba extract for preparing a medicament intended to ease the withdrawal of individuals dependent on the consumption of alcohol, amphetamines, tobacco, drugs inducing toxicomania |
| 09/16/2004 | US20040180080 Fentanyl compound-containing edible patch to be applied to oral mucosa |
| 09/16/2004 | US20040180061 Botulinum toxin therapy for neuropsychiatric disorders |
| 09/16/2004 | US20040180036 Salts of codrugs and uses related thereto |
| 09/16/2004 | US20040180007 Pharmaceutical chewing gum formulations |
| 09/16/2004 | CA2518133A1 Therapeutic agents for drug/substance dependence |
| 09/16/2004 | CA2518020A1 Alpha-keto carbonyl calpain inhibitors |
| 09/16/2004 | CA2517525A1 Posh interacting proteins and related methods |
| 09/16/2004 | CA2517422A1 Tetrahydropyran compounds as tachykinin antagonists |
| 09/16/2004 | CA2517146A1 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators |
| 09/16/2004 | CA2517083A1 Novel aminopyridine derivatives as mglur5 antagonists |
| 09/16/2004 | CA2517081A1 Nitrogen-containing heterocyclic derivatives having 2-6, disubtituted styryl |
| 09/16/2004 | CA2514848A1 Use of adenosine receptor agonists in therapy |
| 09/15/2004 | EP1457557A1 Novel proteins and dnas thereof |
| 09/15/2004 | EP1457495A1 Adenosine A1 receptor agonists |
| 09/15/2004 | EP1457493A1 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists |
| 09/15/2004 | EP1457490A1 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 09/15/2004 | EP1457488A1 Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity |
| 09/15/2004 | EP1457210A1 Remedies and/or preventives for conformational diseases |
| 09/15/2004 | EP1457207A1 Solid compositions containng compounds unstable to oxygen and method for stabilization thereof |
| 09/15/2004 | EP1456653A2 Genes encoding g-protein coupled receptors and methods of use therefor |
| 09/15/2004 | EP1456419A2 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| 09/15/2004 | EP1456408A2 Susceptibility locus for schizophrenia |
| 09/15/2004 | EP1456374A2 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| 09/15/2004 | EP1456365A2 Protein modification and maintenance molecules |
| 09/15/2004 | EP1456357A2 Pluripotent embryonic-like stem cells derived from teeth and uses thereof |
| 09/15/2004 | EP1456355A2 Process for the manufacture of human mononuclear phagocytic leukocytes |
| 09/15/2004 | EP1456353A2 The use of acyl salicylates as heat shock inducers |
| 09/15/2004 | EP1456351A1 New strain of lactic acid bacterium and edible compositions, drugs and veterinary products containing it |
| 09/15/2004 | EP1456239A2 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans |
| 09/15/2004 | EP1456219A1 Crystalline form of a ribofuranosyluronamide derivative; a human adenosine A2a receptor agonist |
| 09/15/2004 | EP1456214A2 Improvements in pharmaceutical compositions |
| 09/15/2004 | EP1456212A1 6-aminomorphinane derivatives, method for the production and use thereof |
| 09/15/2004 | EP1456211A1 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors |
| 09/15/2004 | EP1456210A1 Pyrazolyl-substituted triazoloquinoxalines |
| 09/15/2004 | EP1456209A1 A2a adenosine receptor antagonists |
| 09/15/2004 | EP1456206A1 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| 09/15/2004 | EP1456205A1 Imidazoquinoline derivatives |
| 09/15/2004 | EP1456204A1 Triazolo-quinolin derivatives useful as adenosine receptor ligands |
| 09/15/2004 | EP1456203A1 Ethylene diamine derivatives and their use as orexin-receptor antagonists |
| 09/15/2004 | EP1456202A1 Benzothiazoles |
| 09/15/2004 | EP1456201A1 Benzhydryl derivatives |
| 09/15/2004 | EP1456200A1 Lactams as tachykinin antagonists |
| 09/15/2004 | EP1456199A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer |
| 09/15/2004 | EP1456196A1 Benzothiophenes as adenosine receptor modulators |
| 09/15/2004 | EP1456193A1 PREPARATION OF TRANS-FUSED 3,3a,8,12b-TETRAHYDRO-2 i H /i -DIBENZO 3,4:6,7]CYCLOHEPTA 1,2-b]FURAN DERIVATIVES |
| 09/15/2004 | EP1456189A1 Benzothia(dia)zine derivatives and their use as ampa modulators |
| 09/15/2004 | EP1456188A1 7-amino-benzothiazole derivatives as adenosine receptor ligands |
| 09/15/2004 | EP1456178A1 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
| 09/15/2004 | EP1456172A1 Pyrrolidine-2-ones as factor xa inhibitors |
| 09/15/2004 | EP1456163A2 Improvements in pharmaceutical compositions |
| 09/15/2004 | EP1456160A2 Vitamin d analogues |
| 09/15/2004 | EP1455841A2 Osteopontin-related compositions and methods |
| 09/15/2004 | EP1455837A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics |
| 09/15/2004 | EP1455812A2 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment |
| 09/15/2004 | EP1455795A1 Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
| 09/15/2004 | EP1455794A2 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER |
| 09/15/2004 | EP1455792A1 Ureas of 2-aminobenzothiazoles as adenosine modulators |
| 09/15/2004 | EP1455791A1 Method for administering birb 796 bs |
| 09/15/2004 | EP1455786A1 Use of a compound in the treatment of sleep disorders and the like in providing refreshedness on waking and a method for the treatment of grogginess therewith |
| 09/15/2004 | EP1455785A1 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same |
| 09/15/2004 | EP1455784A1 Analgesic delivery systems and methods of use |
| 09/15/2004 | EP1455782A1 High-concentration stable meloxicam solutions for needle-less injection |